Skip to main content
NeuronFeed

Alchemab Therapeutics vs Pathos AI

Which Drug Discovery AI tool is better in 2026?

Alchemab Therapeutics

$32M

Pathos AI

$467M

Side-by-side

Verdict

Pathos AI is the more established option (raised $467M); pricing is comparable on both sides.

Metric Alchemab Therapeutics Pathos AI
Taglinei
Foundedi 2022🏆
HQi
Employeesi 11-50 11-50
Neuron scorei 66 72🏆
Total fundingi $32M $467M🏆
Latest roundi Series A Series D · May 2025
Valuationi $1.6B🏆
Cheapest paid plani Pricing not disclosed Pricing not disclosed
Free plani
Free triali
Top tier pricei Pricing not disclosed Pricing not disclosed
Pricing summaryi Free Free
Categoriesi

Capability matrix

Developer-facing capabilities and access signals for Alchemab Therapeutics and Pathos AI.

Capability Alchemab Therapeutics Pathos AI
MCP support
Public API
Webhooks
OAuth 2.0
SDK languages
Free plan
Free trial
Verified
Active deal

🟢 Strengths of Alchemab Therapeutics

  • Strong in Drug Discovery

🔵 Strengths of Pathos AI

  • Has raised more capital ($467M vs $32M)
  • Higher Neuron score (72 vs 66)
  • Newer company (2022)

Which should you choose?

Choose Pathos AI if price matters most — it starts at Free, which is friendlier for teams watching burn. Both Drug Discovery tools ship core features, so the cost delta often decides it for small teams and solo operators.

Choose Pathos AI if you want the most established option — it has raised $467M, suggesting more runway for enterprise features, support, and long-term roadmap. For mission-critical workflows or larger teams, that stability often outweighs a lower monthly price.

Frequently asked questions

Alchemab Therapeutics vs Pathos AI — which is better?

It depends on your priority. Alchemab Therapeutics is the leaner option; Pathos AI has broader feature depth. See the side-by-side table above.

Is Alchemab Therapeutics cheaper than Pathos AI?

No — Pathos AI's cheapest paid plan is Free, while Alchemab Therapeutics's is Free.

Do Alchemab Therapeutics and Pathos AI offer free plans?

Alchemab Therapeutics: Yes, has a free plan. Pathos AI: Yes, has a free plan.

Contextual paths to related AI startups, deals and rankings.